ERBB2 and breast carcinoma: PROTACs have received considerable attention in the past several decades since their initial discovery by Sakamoto and Crews [211] and are the subject of numerous clinical trials, notably including the PROTAC ARV-471 currently being studied in Phase 3 clinical trials for patients with ER+/HER2- breast cancer.